This result was in contrast to our results and results from Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) study, which demonstrated that baseline high-sensitive cardiac troponin I (hsTnI) levels were not associated with post-discharge outcomes at 30 days and 180 days [15]. The gene discussed is TNNI3; the disease is hydrops fetalis.